Biotech stocks were down for a second week in a row, as they retreated along with the broader market amid macro concerns. Consumer price inflation data released during the week stoked rate hike fears, and exerted negative pressure on stocks.
There were very few stock-specific catalysts, barring a few preannouncements, stock offerings, and a slew of initial public offerings.
The biggest disappointment of the week was FibroGen, Inc. FGEN, which lost roughly 50% of its market cap following an adverse AdCom verdict on its roxadustat, which is evaluated for treating anemia in chronic kidney disease patients.
Vaccine maker Moderna, Inc. MRNA was a standout this week, as its shares ended the week with a gain of about 22%, closing at an all-time high. In the process, the stock hit a key milestone of $100 billion in market cap.
Eli Lilly and Company LLY announced the acquisition of privately-held Promoter Technologies for over $1 billion, including potential milestone payments. Promoter's portfolio is expected to add value to Lilly's diabetes franchise.
Here are the key catalytic events for the unfolding week:
Mucopolysaccharides 2021, the 16th Annual International Symposium of MPS and Related Diseases: July 23-25
The Food and Drug Administration is expected to rule on Albireo Pharma, Inc.'s ALBO new drug application for odevixibat for the treatment of pruritus in patients with progressive familial intrahepatic cholestasis, a rare inherited progressive liver disease.
Bylvay has been approved as the brand name for odevixibat. The PDUFA goal date is Tuesday, July 20.
Related Link: 18 Key Biopharma Catalysts To Keep An Eye On In Q3
Intuitive Surgical, Inc. ISRG (Tuesday, after the close)
Johnson & Johnson JNJ (Wednesday, before the market open)
Abbott Laboratories ABT (Thursday, before the market open)
Biogen Inc. BIIB (Thursday, before the market open)
Quest Diagnostics Incorporated DGX (Thursday, before the market open)
NeuroMetrix, Inc. NURO (Thursday, before the market open)
AbSci Corp is proposing to offer 12.5 million shares in an initial public offering at an estimated price range of $15-$17. The company's AI-powered Integrated drug creation platform enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process. The company has applied for listing its shares on the Nasdaq under the ticker symbol ABSI.
Candel Therapeutics, Inc., a late clinical stage biopharma focused on helping patients fight cancer with oncolytic viral immunotherapies, has filed to offer 6.072 million shares in an IPO. The company expects to price the offering between $13 and $15 and has applied for listing its shares on the Nasdaq under the ticker symbol CADL.
Elicio Therapeutics, Inc., an oncology-focused clinical-stage biopharma, will offer 3.077 million shares in an IPO, with the price range estimated to be $12 and $14. The company has applied for listing its shares on the Nasdaq under the ticker symbol ELTX.
Ocean Biomedical, Inc. has filed to offer 3.2258 million shares in an IPO. The company expects to price the offering in the range of $14-$17. The biopharma focuses on licensing tech and innovations and developing them into products. It has applied for listing its shares on the Nasdaq under the ticker symbol OCEA.
IPO Quiet Period Expiry
Monte Rosa Therapeutics, Inc. GLUE
Miromatrix Medical Inc. MIRO
Elevation Oncology, Inc. ELEV
Acurx Pharmaceuticals, Inc. ACXP
Graphite Bio, Inc. GRPH
G Medical Innovations Holdings Ltd GMVD
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.
All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.
Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.
Rate collection and criteria: Click here for more information on rate collection and criteria.